The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Treating older patients with AML in 2020: What is new and promising?

Jun 24, 2020

During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the treatment of elderly patients with AML in 2020.

Courtney DiNardo discusses highlights including the Viale-A trial (evaluating azacitidine + venetoclax for newly diagnosed AML), identifying the benefit of oral azacitidine maintenance, the use of IDH1/2 and FLT-3 inhibitors in the relapsed/refractory setting, the p53 modulating compound APR-246, and the CD47 monoclonal antibody magrolimab.

Treating older patients with AML in 2020: What is new and promising?